- Home
- BIIB vs FSLR Comparison
BIIB vs FSLR Comparison
Compare BIIB & FSLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FSLR
- Stock Information
- Founded
- BIIB 1978
- FSLR 1999
- Country
- BIIB United States
- FSLR United States
- Employees
- BIIB N/A
- FSLR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FSLR Semiconductors
- Sector
- BIIB Health Care
- FSLR Technology
- Exchange
- BIIB Nasdaq
- FSLR Nasdaq
- Market Cap
- BIIB 25.1B
- FSLR 21.3B
- IPO Year
- BIIB 1991
- FSLR 2006
- Fundamental
- Price
- BIIB $160.85
- FSLR $207.51
- Analyst Decision
- BIIB Buy
- FSLR Strong Buy
- Analyst Count
- BIIB 25
- FSLR 25
- Target Price
- BIIB $258.57
- FSLR $280.74
- AVG Volume (30 Days)
- BIIB 1.7M
- FSLR 3.4M
- Earning Date
- BIIB 10-30-2024
- FSLR 10-29-2024
- Dividend Yield
- BIIB N/A
- FSLR N/A
- EPS Growth
- BIIB 10.05
- FSLR 162.15
- EPS
- BIIB 11.06
- FSLR 11.61
- Revenue
- BIIB $9,607,500,000.00
- FSLR $3,850,811,000.00
- Revenue This Year
- BIIB N/A
- FSLR $29.09
- Revenue Next Year
- BIIB N/A
- FSLR $32.05
- P/E Ratio
- BIIB $14.54
- FSLR $17.88
- Revenue Growth
- BIIB N/A
- FSLR 21.77
- 52 Week Low
- BIIB $153.62
- FSLR $135.88
- 52 Week High
- BIIB $268.30
- FSLR $306.77
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- FSLR 57.46
- Support Level
- BIIB $158.44
- FSLR $181.76
- Resistance Level
- BIIB $165.29
- FSLR $212.15
- Average True Range (ATR)
- BIIB 4.09
- FSLR 8.91
- MACD
- BIIB 1.04
- FSLR 3.07
- Stochastic Oscillator
- BIIB 32.51
- FSLR 86.06
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FSLR First Solar Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.